This test is most useful if any of these apply to you.
If you've had discharge or odor that keeps coming back, or you're pregnant and want to know what's living in your vaginal microbiome, this result tells you whether B. fragilis (Bacteroides fragilis) has moved into your vagina. It's a gut bacterium, and in most healthy women it isn't found there at all. When it does show up, it tends to come with conditions where the vagina's protective bacteria have been pushed aside, such as bacterial vaginosis and some pelvic infections.
This is a research-grade measurement. There are no validated reference ranges, and a positive result on its own hasn't been shown to predict any specific disease. Read it as one clue alongside the rest of your vaginal panel and how you feel.
B. fragilis is a rod-shaped bacterium that can't survive in oxygen and lives mainly in the lower intestine. Your body doesn't make it, so this test measures whether the bacterium is present in your vaginal sample and how much of it there is. A healthy vagina is usually dominated by Lactobacillus species, which keep the environment acidic and crowd out other microbes.
That's why most healthy women don't carry B. fragilis in the vagina, though older reports put the rate as high as about 16% in some groups of healthy nonpregnant women. It's more often part of the mixed overgrowth of oxygen-avoiding bacteria that appears when the lining is disrupted.
| Who Was Studied | What Was Compared | What They Found |
|---|---|---|
| Pregnant women at delivery (120 women, Poland) | How often it turned up on vaginal swabs | Found in 6.6% |
| Healthy nonpregnant women, older reports | How often it turned up in cervical and vaginal samples | Ranged from none up to about 16% |
Source: Leszczyński et al. for pregnant women; the up-to-16% figure comes from older reviews of pelvic anaerobic infection.
What this means for you: a positive result puts you in a minority of healthy women, and it often means something has disturbed the local balance. It can't tell you by itself whether that disturbance is an infection that needs treatment. That's why the rest of your panel and your symptoms matter so much.
Bacterial vaginosis is the most common form of vaginal imbalance. Lactobacillus fades, and a mixed group of oxygen-avoiding bacteria takes over. In women with bacterial vaginosis, B. fragilis can turn up in that mix along with Prevotella and Gardnerella vaginalis. It isn't one of the organisms that defines bacterial vaginosis, though.
B. fragilis also makes sialidase. This enzyme breaks down the protective mucus coating the vaginal lining. Sialidase activity in vaginal fluid closely tracks bacterial vaginosis. Early work pointed to Bacteroides and Prevotella species as its main sources, while more recent research points to Gardnerella vaginalis as a dominant source. Vaginal communities low in Lactobacillus and rich in oxygen-avoiding bacteria are also linked to an inflamed cervix (cervicitis), but there's no reliable figure for how often B. fragilis itself turns up in cervicitis.
B. fragilis makes up only a small share of normal gut bacteria, yet it's the oxygen-avoiding bacterium most often recovered from abscesses outside the intestine, including in the pelvis. In gynecology it shows up in pelvic inflammatory disease, infection of the uterine lining (endometritis), septic abortion, and abscesses of the fallopian tubes, ovaries and Bartholin's glands. Those findings come from infected tissue and pus. No study has shown that a positive vaginal swab predicts one of these infections.
When it does cause an infection, treatment is harder than usual. In lab testing of infection isolates, more than 90% resisted penicillin and clindamycin resistance was common. Resistance ran from 2% to 20% for carbapenems and from 0.2% to 4% for metronidazole.
What this means for you: a positive swab with no symptoms isn't an infection. If you have pelvic pain, fever or a tender lump near the vaginal opening, though, a positive result is a reason to get examined soon, and any treatment should be guided by a culture with antibiotic sensitivity testing.
Pregnancy is where the vaginal evidence gets closest to a real outcome, and it's still thin. A study in China followed 273 pregnant women and swabbed them in each trimester. It found a weak link between B. fragilis in the second trimester and spontaneous preterm birth. The bacterium turned up in very few samples from either group, though, and the link didn't hold up after the researchers adjusted for age, weight and obstetric history and corrected for testing many bacteria at once.
The stronger finding in that study was about stability. Women whose vaginal bacterial communities shifted more across pregnancy were more likely to deliver early, so the pattern across trimesters tells you more than any single bacterium does.
Older work found the toxin-producing strain in about 1% of pregnant women's vaginal swabs. The strains were genetically unrelated to each other, with no sign that they were spreading inside hospitals. A mother's bacteria also seed her baby: infants born vaginally carry more B. fragilis in their gut through roughly the first 14 months than babies born by cesarean. That finding comes from infant stool, not vaginal swabs.
Most headlines about this bacterium come from colon research, and that research points in two directions. A pooled analysis of 14 studies of stool and colon samples found that strains carrying a toxin gene were about two and a half times as common in people with colorectal cancer as in healthy controls. The toxin damages the seal between the cells lining the gut.
Strains without the toxin look different. They're being studied as possible probiotics, and in one study of people with chronic hepatitis B, lower gut levels of B. fragilis went along with more liver inflammation.
The findings fit together once you see that the bacterium's effect depends on where it lives and which strain it is. In the gut it's a normal resident, and what it does depends on whether it carries the toxin. In the vagina it's out of place, and its presence mainly signals that the protective bacteria have been displaced. A vaginal result says nothing about your colon cancer risk, and a standard count doesn't tell you whether your strain carries the toxin gene.
With the vaginal microbiome, change over time probably carries more weight than one snapshot, since instability across pregnancy was the finding tied to preterm birth. Gut studies show the same thing in general terms. Each person's bacterial makeup is recognizably their own, but it drifts: in one long-term study, similarity between samples from the same person fell from 63.5% a month apart to 40.7% three years apart. That's whole-community data from stool, not B. fragilis on vaginal swabs, but it's a good reason not to over-read any single result.
No study has set a retesting schedule for this marker. A reasonable approach is to get a baseline when you feel well, then retest in 3 to 6 months, or after you've finished treatment for an infection and your symptoms have settled. If you're pregnant or planning to be, a swab each trimester matches how the research was done. Without standard cutpoints, your own trend is the most useful comparison you have.
What a positive result means depends almost entirely on what comes with it. Read it against the rest of your vaginal panel and your symptoms, then follow the pattern that fits.
If you're pregnant, share the result with your obstetrician along with your other vaginal findings. A single positive swab doesn't predict preterm birth, but it's useful context if later swabs show your vaginal bacteria shifting.
Bacteroides Fragilis is best interpreted alongside these tests.
Bacteroides Fragilis is included in these pre-built panels.
Comprehensive PCR profile of 48 markers across beneficial flora, opportunistic bacteria, STIs, viruses, and fungal pathogens.